Frontlight ResearchEarly access
SuspendedNo phase
Assessment of Patients With Acute Pouchitis Treated With Antibiotics
Key facts
- Who runs it
- Alimentiv Inc.
- Where
- Cleveland and New York, United StatesSee the 2 sitesAlso in 2 other countries, 2 sites
- Trial code
- Status
- Suspended
- People taking part
- 43 people, planned
- Started
- 7 Dec 2021
- Ended
- 9 Dec 2024
- Type of study
- Observational
- Treatments tested
- Observational, No intervention
- Record updated
- 20 February 2024
- Why it stopped
- This decision has been made after careful consideration and evaluation of trial progress and ongoing recruitment challenges.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Adult patients ≥ 18 years of age
- IPAA for UC (J-pouch only) ≥ 6 months prior to screening
- Diagnosis of acute pouchitis at screening by stool frequency (an absolute value of ≥ 6 stools / day AND an increase of ≥ 3 stools / day above the post-IPAA baseline), and local endoscopy (presence of ≥ 1 erosion or ulceration of the pouch on endoscopy [not including ulceration occurring within 1 cm of the pouch staple or pouch suture line])
- Not currently taking antibiotics for pouchitis or previous systemic antibiotic use for any reason within 4 weeks of screening. Prior to the Screening pouchoscopy. Note: Initiation of antibiotics for treatment of acute pouchitis prior to the Screening pouchoscopy will be permitted only if the participant initiates treatment within 48 hours prior to the Screening pouchoscopy; use outside of the 48-hour window will not be permitted and these patients should not be included in the study
- Current treatment with 5-aminosalicylic acid drugs, immunosuppressants, antidiarrheals, antimotility agents, and probiotics is permitted, if patient has received a stable dose for ≥ 4 weeks prior to screening. Dose of concomitant therapy must remain stable during the study period
- Able to participate fully in all aspects of this clinical trial
- Written informed consent must be obtained and documented
Who cannot take part
- Antibiotic-dependent pouchitis, defined by ≥ 3 months of cumulative antibiotic use over the 12 months prior to screening
- Anticipated changes in therapy during study period
- Use of oral corticosteroids. Participants must have discontinued oral corticosteroids within 1 month prior to screening
- Current use of any advanced oral small molecule drug (e.g Janus kinase [JAK] inhibitors for the treatment of pouchitis. Participants must have discontinued oral small molecule therapy within 2 weeks prior to screening
- Failed (i.e., inadequate response with, loss of response to, or intolerance to) 2 or more compounds or classes of advanced therapies such as biologics and/or small molecule drugs (i.e., 1 biologic and 1 JAK inhibitor, 2 biologics in the same class, or 2 biologics from different classes) for the treatment of pouchitis
- Prior enrollment in the current study
- Pouchitis caused by other inflammatory etiologies (e.g., ischemia or infection)
- Known Crohn's disease (CD) or suspected CD of the pouch, defined as complex perianal/pouch fistula and/or extensive length of prepouch ileitis with deep ulceration
- Serious underlying disease other than acute pouchitis and UC that in the opinion of the investigator may interfere with the participant's ability to participate fully in the study
- History of alcohol or drug abuse that in the opinion of the investigator may interfere with the participant's ability to comply with the study procedures
- Known history of allergy, intolerance, or are refractory to ciprofloxacin AND metronidazole AND any component of amoxicillin/potassium clavulanate combination
- Pouch formations besides J-pouch (e.g., W-, S- and Kock pouches)
- IPAA for familial adenomatous polyposis
- Isolated cuffitis, pouch-anal or pouch-ileal anastomotic stricture, perforating complications, or pelvic sepsis
- Participant who are pregnant or breastfeeding
- Unable to undergo endoscopic evaluation
Where in United States
Also in 2 other countries, 2 sites
- Cleveland ClinicCleveland, United States
- Mount Sinai HospitalNew York, United States
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the reliability and responsiveness of symptoms, endoscopic, and histological items for assessing pouchitis disease activity in patients undergoing standard of care (SOC) antibiotic therapy for treatment of pouchitis, in order to develop a novel pouchitis disease activity index.
The group in the trial
- Open-label observational study
This study will evaluate the reliability and responsiveness of patient-reported symptoms and endoscopic and histologic items for assessing pouchitis disease activity in 43 patients undergoing standard of care (SOC) antibiotic therapy.
Treatment: Observational, No intervention
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Assessment of Patient-reported Symptoms and Endoscopic, Histologic, and Biomarker Outcomes in Patients With Acute Pouchitis Treated With Antibiotics
- Record updated
- 20 February 2024